Drug Induced Liver Injury

UMLS: C0860207
Basic Information
Severity Level:
Moderate
UMLS ID:
C0860207
MeSH ID:
D056486
Synonyms:
Drug Induced Liver Injury
Drug Induced Hepatotoxicity
Drug-Induced Disorder Of Liver
Drug-Induced Liver Injury
Disease Drug Induced Liver
Diseases Drug Induced Liver
Diseases Drugs Inducing Liver
Drug-Induced Liver Disease
Pharmacogenomic Information
PharmGKB
PharmGKB References:
PA166119041

Risk-Increasing Variants (81)

CYP2B6*1, CYP2B6*6
Effect: Risk Increase
CYP3A5*1, CYP3A5*3
Effect: Risk Increase
GSTM1 non-null, GSTM1 null
Effect: Risk Increase
HLA-A*01:01
Effect: Risk Increase
HLA-A*02:01
Effect: Risk Increase
HLA-A*03:01
Effect: Risk Increase
HLA-A*30:02
Effect: Risk Increase
HLA-A*31:01
Effect: Risk Increase
HLA-A*32:01
Effect: Risk Increase
HLA-A*33:01
Effect: Risk Increase
HLA-B*08:01
Effect: Risk Increase
HLA-B*15:18
Effect: Risk Increase
HLA-B*35:02
Effect: Risk Increase
HLA-B*35:03
Effect: Risk Increase
HLA-B*39:01
Effect: Risk Increase
HLA-B*52:01
Effect: Risk Increase
HLA-B*53:01
Effect: Risk Increase
HLA-B*57:01
Effect: Risk Increase
HLA-B*57:03
Effect: Risk Increase
HLA-B*58:01
Effect: Risk Increase
HLA-C*06:02
Effect: Risk Increase
HLA-C*12:03
Effect: Risk Increase
HLA-DPB1*10:01
Effect: Risk Increase
HLA-DQA1*02:01
Effect: Risk Increase
HLA-DQB1*02:01
Effect: Risk Increase
HLA-DQB1*03:03
Effect: Risk Increase
HLA-DQB1*05:01, HLA-DQB1*05:02, HLA-DQB1*05:03
Effect: Risk Increase
HLA-DQB1*05:02
Effect: Risk Increase
HLA-DQB1*06:02
Effect: Risk Increase
HLA-DRB1*03:01
Effect: Risk Increase
HLA-DRB1*04:03
Effect: Risk Increase
HLA-DRB1*04:04
Effect: Risk Increase
HLA-DRB1*07:01
Effect: Risk Increase
HLA-DRB1*15:01
Effect: Risk Increase
HLA-DRB1*16:01
Effect: Risk Increase
NAT2 slow acetylator
Effect: Risk Increase
NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14
Effect: Risk Increase
NAT2*4, NAT2*5, NAT2*6, NAT2*7
Effect: Risk Increase
NAT2*4, NAT2*6
Effect: Risk Increase
NAT2*4, NAT2*6, NAT2*7
Effect: Risk Increase
NAT2*4, NAT2*6, NAT2*7, NAT2*16
Effect: Risk Increase
NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16
Effect: Risk Increase
NAT2*5, NAT2*6, NAT2*7
Effect: Risk Increase
NAT2*6, NAT2*7
Effect: Risk Increase
SLCO1B1*15
Effect: Risk Increase
rs1041983
Effect: Risk Increase
rs1061472
Effect: Risk Increase
rs10946737
Effect: Risk Increase
rs10946739
Effect: Risk Increase
rs1128503
Effect: Risk Increase
rs114577328
Effect: Risk Increase
rs116561224
Effect: Risk Increase
rs117491755
Effect: Risk Increase
rs1363907
Effect: Risk Increase
rs1495741
Effect: Risk Increase
rs1695
Effect: Risk Increase
rs1799929
Effect: Risk Increase
rs1799930
Effect: Risk Increase
rs1799931
Effect: Risk Increase
rs1862167
Effect: Risk Increase
rs2032582
Effect: Risk Increase
rs2205986
Effect: Risk Increase
rs2231142
Effect: Risk Increase
rs246221
Effect: Risk Increase
rs2476601
Effect: Risk Increase
rs28371759
Effect: Risk Increase
rs2858996
Effect: Risk Increase
rs3129880
Effect: Risk Increase
rs319952
Effect: Risk Increase
rs320003
Effect: Risk Increase
rs352139
Effect: Risk Increase
rs35719165
Effect: Risk Increase
rs393994
Effect: Risk Increase
rs4880
Effect: Risk Increase
rs536560
Effect: Risk Increase
rs72631546
Effect: Risk Increase
rs7439366
Effect: Risk Increase
rs7574865
Effect: Risk Increase
rs7662029
Effect: Risk Increase
rs7958375
Effect: Risk Increase
rs9274407
Effect: Risk Increase

Risk-Decreasing Variants (10)

CYP2B6*1, CYP2B6*6
Effect: Risk Decrease
HLA-DQB1*02:01
Effect: Risk Decrease
HLA-DQB1*06:02
Effect: Risk Decrease
HLA-DRB1*07:01
Effect: Risk Decrease
HLA-DRB1*15:03
Effect: Risk Decrease
NAT2*16
Effect: Risk Decrease
NAT2*4
Effect: Risk Decrease
SLCO1B1*1, SLCO1B1*15, SLCO1B1*37
Effect: Risk Decrease
rs1139130
Effect: Risk Decrease
rs4149014
Effect: Risk Decrease
Total Variants: 91
Risk Increase: 81
Risk Decrease: 10
Classification Hierarchy
MeSH Tree Number breakdown for C0860207
C06
Digestive System Diseases
Category: Digestive System Diseases Parent: C (Diseases) Level: 0
C06.552
Liver Diseases
Category: Digestive System Diseases Parent: C06 Level: 1
C06.552.100
Chemical and Drug Induced Liver Injury
Category: Digestive System Diseases Parent: C06.552 Level: 2 Tree Number: C06.552.100
C25
Chemically-Induced Disorders
Category: Chemically-Induced Disorders Parent: C (Diseases) Level: 0
C25.100
Drug-Related Side Effects and Adverse Reactions
Category: Chemically-Induced Disorders Parent: C25 Level: 1 Tree Number: C25.100
C25
Chemically-Induced Disorders
Category: Chemically-Induced Disorders Parent: C (Diseases) Level: 0
C25.723
Poisoning
Category: Chemically-Induced Disorders Parent: C25 Level: 1 Tree Number: C25.723
Similar ADEs in This Classification
Mycetismus
UMLS: C0026865
33%
Failure;Hepatic
UMLS: C0085605
30%
Chronic Fluoride Poisoning
UMLS: C0016325
29%
Food Poisoning
UMLS: C0016479
29%
Gas Poisoning
UMLS: C0017107
29%
Fungal Poisoning
UMLS: C0026953
29%
Plant Poisoning
UMLS: C0032087
29%
Anticholinergic Syndrome
UMLS: C0151500
29%
Heavy Metal Poisoning
UMLS: C0274869
29%
Carbon Tetrachloride Causing Toxic Effect
UMLS: C0392622
29%
Foodborne Illness
UMLS: C0679360
29%
Organic Phosphate Poisoning
UMLS: C0700359
29%
ADE Molecular Mechanism Mapping

Drug-ADE-Human Protein Triplets

Molecular mechanism triplets showing drug-adverse event-protein relationships

5661 Total Triplets
530 High Confidence
Loading Drug-ADE-Protein triplets...
Personalized Drug-Protein-ADE Network

Comprehensive Information for Personalized ADE

Comprehensive Information and Reliability for Drug-ADE Association

Drug Confidence Filter
DTA Confidence Level
Layout Style
Show Labels
Total Drugs
1621
64 High | 171 Medium | 1386 Low Confidence
Total Proteins
262
Target proteins associated with this ADE
Drug-Protein-ADE association
12863
159 Known | 371 High | 5131 Middle | 7202 Low Confidence
Confidence Profile
44%
Known/High/Middle-confidence interactions

This interactive network visualization shows the relationships between the top 50 drugs (ranked by case number) out of 1621 total drugs associated with this adverse event, their known and potential off-target proteins, and the associated adverse effect. The connections indicate binding interactions and mechanistic pathways.

Adverse Drug Event (ADE)
Drug
Protein
Drug-Center
Human Protein-Center
confidence level

Drug Confidence Level Distribution

Drug Type Distribution

Loading ADE information...

Pharmacological Target Class Distribution

Top 8 Function Target Sub Classes

Loading target information...
The Introduction of Drug-AE Confidence Score Grade
Priority Level Score Range Description Evidence Characteristics
High Score ≥ 6.67
High-priority associations requiring immediate attention. 		Strong evidence across multiple dimensions with high statistical significance, robust association measures, and substantial case numbers. Warrant priority pharmacovigilance action. High P-value scores (significant Adjust-P), Strong ROR/PRR values, Substantial case numbers, Complete dimensional coverage, Minimal data filtering needed.
Medium 3.33 ≤ Score < 6.67
Medium-priority associations requiring careful evaluation.		 Moderate evidence quality with acceptable statistical significance and association strength. May need additional validation or monitoring before definitive action. Moderate P-value significance, Reasonable ROR/PRR measures, Adequate case numbers, Partial dimensional coverage, Some data quality considerations.
Low Score < 3.33
Low-priority associations with limited evidence strength. 		May represent weak signals, insufficient data, or associations requiring extensive additional investigation before any regulatory or clinical consideration. Weak P-value significance, Low association measures, Limited case numbers, Incomplete dimensional data, Significant data filtering applied.
PersDTA overview
The Introduction of Drug-AE Severity Score Grade
Severity Level Score Range Description Typical outcomes
Minimal 0 ≤ Score ≤ 0.387
Low severity ADRs requiring minimal intervention.		 Events that need medical attention to prevent permanent damage but without hospitalization or life-threatening consequences. Primarily RI (Required Intervention) outcomes, Outpatient management, Preventive measures, Early intervention prevents escalation.
Mild 0.387 < Score ≤ 0.861
Mild severity events requiring hospitalization.		 Mix of intervention-required and hospitalization cases with manageable clinical outcomes and good recovery potential. Mix of RI and HO outcomes, Initial or prolonged hospitalization, Active medical management, Generally favorable prognosis.
Moderate 0.861 < Score ≤ 1.500
Moderate ADRs resulting in permanent disability.		 Higher proportion of hospitalization and disability cases requiring intensive medical management and long-term care planning. Increased HO and DS outcomes, Permanent disability, Extended hospitalization, Rehabilitation required, Long-term functional impairment.
Severe 1.500 < Score ≤ 2.52
High severity life-threatening events with significant morbidity.		 Notable presence of disability and life-threatening outcomes requiring emergency intervention and intensive care management. Prominent DS and LT outcomes, Life-threatening events, Emergency intervention required, ICU admission, High risk of permanent consequences.
Critical 2.524 < Score ≤ 5.000
Critical life-threatening or fatal ADRs with maximum clinical impact.		 High proportion of life-threatening events and deaths with very strong drug-event associations requiring immediate regulatory action. Significant LT and DE outcomes, Fatal events, Emergency life-support measures, Immediate drug discontinuation, Regulatory safety alerts.
The Introduction of Drug-AE-Protein Confidence Score Grade
Confidence Level Relationships Description Evidence Types
Known/Valid Direct DTA relationships The drug-ADE, drug-target, and target-ADE associations are all derived from the same literature source. Experimental validation, Clinical evidence
High DT + TA + DA Two of the three associations (drug-ADE, drug-target, and target-ADE) are derived from the same literature source, while the third is validated by other literature. Multiple corroborating sources
Medium DT + TA + DA Two of the three associations (drug-ADE, drug-target, and target-ADE) are validated by separate literature sources. Partial evidence chain
Low TA + DT Only target-ADE and drug-target associations are validated by literature sources. Associative evidence only
Personalized ADE

Route and Formulation-specified Associations

Pharmaceutic Granularity for Route and Formulation specification

Administration Routes (Total: 5781 cases across 23 routes)

Dosage Forms (Total: 4803 cases across 27 forms)

Drug Route Analysis
Drug Form Analysis

Drug Route Analysis

Route Drug Name Case Number Confidence Score Confidence Level Severity Score Severity Level Details
Loading data...

Drug Form Analysis

Form Drug Name Case Number Confidence Score Confidence Level Severity Score Severity Level Details
Loading data...

Disease-stratified Associations

Personalized Granularity for Disease and Indication Stratification

Indication Name
Drug Name
Case Number
Confidence Score
Confidence Level
Severity Score
Severity Level
Details